Alnylam Pharmaceuticals, Inc.

NasdaqGS:ALNY 주식 보고서

시가총액: US$31.2b

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Alnylam Pharmaceuticals 미래 성장

Future 기준 확인 5/6

Alnylam Pharmaceuticals (는) 각각 연간 63.8% 및 19.5% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 63.2% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 87% 로 예상됩니다.

주요 정보

63.6%

수익 성장률

63.1%

EPS 성장률

Biotechs 수익 성장24.2%
매출 성장률19.9%
향후 자기자본 수익률96.4%
애널리스트 커버리지

Good

마지막 업데이트28 Jun 2024

최근 미래 성장 업데이트

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Just Released Its Full-Year Earnings: Here's What Analysts Think

Feb 18
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Just Released Its Full-Year Earnings: Here's What Analysts Think

Recent updates

RNAi: Winning In The Clinic, Now For The Market

Jun 25

Upcoming Pivotal HELIOS-B Data Looms Large For Alnylam's Valuation

Jun 03

Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Price Is Right But Growth Is Lacking

Mar 19
Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Price Is Right But Growth Is Lacking

Is Alnylam's HELIOS-B Delay A Red Flag?

Mar 10

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Just Released Its Full-Year Earnings: Here's What Analysts Think

Feb 18
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Just Released Its Full-Year Earnings: Here's What Analysts Think

Alnylam's Huge Opportunity

Jan 12

Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Price Is Out Of Tune With Revenues

Dec 18
Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Price Is Out Of Tune With Revenues

Unpleasant Surprises Could Be In Store For Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Shares

Jun 23
Unpleasant Surprises Could Be In Store For Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Shares

Is Alnylam Pharmaceuticals (NASDAQ:ALNY) Weighed On By Its Debt Load?

Oct 25
Is Alnylam Pharmaceuticals (NASDAQ:ALNY) Weighed On By Its Debt Load?

Alnylam gets FDA nod for expanded use of rare disease drug Oxlumo

Oct 07

Alnylam: Onpattro's Position In The ATTR Amyloidosis Cardiomyopathy Market

Sep 26

Alnylam RNAi therapy for rare protein disorder gets EU approval

Sep 20

Alnylam to offer $900M convertible senior notes

Sep 12

Alnylam says trial of RNAi therapeutic cemdisiran achieves goals for IgA nephropathy

Aug 29

Alnylam discovery of genetic mutations could lead to therapies for diabetes, obesity

Aug 18

APOLLO Hits A Bullseye, And Alnylam Logs Another Major Clinical Win

Aug 04

수익 및 매출 성장 예측

NasdaqGS:ALNY - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜수익수익잉여 현금 흐름작전 현금평균 애널리스트 수
12/31/20263,09330869976322
12/31/20252,301-226814529
12/31/20241,875-455-297-17829
3/31/20242,003-332128189N/A
12/31/20231,828-44042104N/A
9/30/20231,724-510-672N/A
6/30/20231,237-1,064-541-473N/A
3/31/20231,143-1,065-605-537N/A
12/31/20221,037-1,131-613-541N/A
9/30/2022961-1,182-632-559N/A
6/30/2022884-981-660-578N/A
3/31/2022880-893-654-577N/A
12/31/2021844-853-718-642N/A
9/30/2021749-838-691-615N/A
6/30/2021688-887-653-591N/A
3/31/2021571-876-672-604N/A
12/31/2020493-858-685-615N/A
9/30/2020401-891-775-688N/A
6/30/2020345-846-871-760N/A
3/31/2020286-886-452-336N/A
12/31/2019220-886-419-278N/A
9/30/2019169-821-372-233N/A
6/30/2019101-858-352-204N/A
3/31/201986-802-745-595N/A
12/31/201875-761-690-563N/A
9/30/201892-692-625-515N/A
6/30/2018107-570-550-460N/A
3/31/201893-525-527-438N/A
12/31/201790-491N/A-383N/A
9/30/201769-462N/A-358N/A
6/30/201766-443N/A-335N/A
3/31/201759-414N/A-324N/A
12/31/201647-410N/A-308N/A
9/30/201637-388N/A-282N/A
6/30/201630-361N/A-261N/A
3/31/201630-342N/A-247N/A
12/31/201541-290N/A-189N/A
9/30/201558-221N/A-173N/A
6/30/201562-188N/A-159N/A
3/31/201561-160N/A-150N/A
12/31/201451-360N/A-166N/A
9/30/201437-371N/A-151N/A
6/30/201435-357N/A-132N/A
3/31/201437-331N/A-109N/A
12/31/201347-89N/A-69N/A
9/30/201345-119N/A-115N/A
6/30/201353-109N/A-88N/A

애널리스트 미래 성장 예측

수입 대 저축률: ALNY 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률( 2.4% )보다 빠른 성장으로 간주됩니다.

수익 vs 시장: ALNY (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.

고성장 수익: ALNY 향후 3년 내에 수익을 낼 것으로 예상됩니다.

수익 대 시장: ALNY 의 수익(연간 19.5% ) US 시장( 8.7% 보다 빠르게 성장할 것으로 예상됩니다. 8.7% 연간).

고성장 수익: ALNY 의 수익(연간 19.5% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.


주당 순이익 성장 예측


미래 자기자본 수익률

미래 ROE: ALNY 의 자본 수익률은 3년 내에 매우 높을 것으로 예상됩니다( 87 %).


성장 기업 발견